title: Is it relevant to use an interleukin-1-inhibiting strategy for the treatment of patients with deficiency of interleukin-36 receptor antagonist?
authors.affiliation: Department of Genetics, INSERM U781, Imagine Institute, 24 boulevard Montparnasse, 75015, Paris, France; Department of Dermatology, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Sorbonne Paris Cité Université Paris Diderot, Paris, France.
authors.forename: M
authors.initials: M
authors.lastname: Tauber
authors.forename: M
authors.initials: M
authors.lastname: Viguier
authors.forename: C
authors.initials: C
authors.lastname: Le Gall
authors.forename: A
authors.initials: A
authors.lastname: Smahi
authors.forename: H
authors.initials: H
authors.lastname: Bachelez
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use*; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein / Q000627:therapeutic use*; D008297:Male; D018123:Receptors, Interleukin / Q000172:deficiency*
chemical_list: D018501:Antirheumatic Agents; D053590:Interleukin 1 Receptor Antagonist Protein; D018123:Receptors, Interleukin